Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-16-133331
Filing Date
2016-07-19
Accepted
2016-07-19 17:13:51
Documents
2
Period of Report
2016-07-19

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 4991
2 POA DOCUMENT poa.txt EX-24.3_667399 3801
  Complete submission text file 0001209191-16-133331.txt   10188
Mailing Address ARYX THERAPEUTICS,INC. 6300 DUMBARTON CIRCLE FREMONT CA 94555
Business Address
Nagler David (Reporting) CIK: 0001416175 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37833 | Film No.: 161774039

Mailing Address 101 MONTGOMERY STREET, SUITE 2650 SAN FRANCISCO CA 94104
Business Address 101 MONTGOMERY STREET, SUITE 2650 SAN FRANCISCO CA 94104 415-638-6556
Audentes Therapeutics, Inc. (Issuer) CIK: 0001628738 (see all company filings)

EIN.: 461606174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)